Lexeo Therapeutics, Inc.
LXEONasdaq
$4.69
↑ +2.9%Jul 17 close · end-of-day
Price
1Y↑ +11.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$380.8M
Enterprise Value
$187.7M
P/E
—
P/S
—
P/B
1.6
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$87.5M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-37.8%
ROIC
-200.9%
Debt / Equity
—
Net Cash
$193.0M
Return 1Y
+10.1%
Company profile
We are a clinical stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Our principal executive offices are located at 345 Park Avenue South, Floor 6, New York, New York.
- CEO
- R. Nolan Townsend
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- New York
- Website
- www.lexeotx.com
Management & directors
- Bhalla Narinder PalChief Medical Officer
- Otero Jose ManuelChief Operating Officer
- Tamayo Louis EdwardChief Financial Officer
- Townsend Richard NolanChief Executive Officer
- Adler EricChief Medical Officer
- Robertson JennyChief Legal Officer
- See Tai SandiChief Development Officer
Roles derived from SEC Form 4 filings.
Earnings
LXEO Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.25↓ -74.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $654,000.00 | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$60.5M | -$68.5M | -$105.8M | -$109.3M |
| Net income | -$59.3M | -$66.4M | -$98.3M | -$100.0M |
| Diluted EPS | -$36.36 | -$12.40 | -$3.09 | -$1.86 |
| Operating cash flow | -$54.6M | -$59.5M | -$81.2M | -$98.6M |
| Free cash flow | -$55.2M | -$59.6M | -$81.6M | -$99.0M |
| Gross margin | — | — | — | — |
| Operating margin | -9252.1% | — | — | — |
| Net margin | -9063.8% | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$23.6M | -$31.5M | -$27.4M | -$33.8M | -$30.7M | -$21.6M | -$23.1M | -$22.3M |
| Net income | -$21.2M | -$29.5M | -$25.9M | -$32.7M | -$26.1M | -$20.3M | -$21.0M | -$20.2M |
| Diluted EPS | -$0.64 | -$0.89 | -$0.79 | -$0.99 | -$0.60 | -$0.33 | $0.06 | -$0.25 |
| Operating cash flow | -$20.2M | -$17.8M | -$28.3M | -$21.7M | -$27.2M | -$29.5M | -$20.1M | -$21.1M |
| Free cash flow | -$20.4M | -$17.9M | -$28.3M | — | — | -$29.8M | — | -$21.2M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-01 | Townsend Richard Nolan· Chief Executive Officer | Sale | 25,947 | $4.48 | $116,242.56 | filing |
| 2026-07-01 | Bhalla Narinder Pal· Chief Medical Officer | Sale | 22,306 | $4.42 | $98,592.52 | filing |
| 2026-07-01 | Otero Jose Manuel· Chief Operating Officer | Sale | 4,666 | $4.48 | $20,903.68 | filing |
| 2026-07-01 | Tamayo Louis Edward· Chief Financial Officer | Sale | 4,641 | $4.49 | $20,838.09 | filing |
| 2026-06-29 | Tamayo Louis Edward· Chief Financial Officer | Award | 12,000 | $0.00 | $0.00 | filing |
| 2026-06-29 | Otero Jose Manuel· Chief Operating Officer | Award | 12,060 | $0.00 | $0.00 | filing |
| 2026-06-29 | Bhalla Narinder Pal· Chief Medical Officer | Award | 55,000 | $0.00 | $0.00 | filing |
| 2026-06-29 | Townsend Richard Nolan· Chief Executive Officer | Award | 67,000 | $0.00 | $0.00 | filing |
| 2026-05-18 | Townsend Richard Nolan· Chief Executive Officer | Sale | 3,342 | $5.06 | $16,926.90 | filing |
| 2026-05-18 | Otero Jose Manuel· Chief Operating Officer | Sale | 1,302 | $5.07 | $6,606.35 | filing |
| 2026-04-06 | Townsend Richard Nolan· Chief Executive Officer | Sale | 55,000 | $5.69 | $313,137.00 | filing |
| 2026-03-13 | Otero Jose Manuel· Chief Operating Officer | Award | 5,930 | $2.64 | $15,678.92 | filing |
| 2026-03-13 | Townsend Richard Nolan· Chief Executive Officer | Award | 2,623 | $2.64 | $6,935.21 | filing |
| 2026-02-18 | Townsend Richard Nolan· Chief Executive Officer | Sale | 10,173 | $6.38 | $64,924.09 | filing |
| 2026-02-18 | Otero Jose Manuel· Chief Operating Officer | Sale | 3,016 | $6.40 | $19,293.96 | filing |
| 2026-02-13 | Bhalla Narinder Pal· Chief Medical Officer | Award | 49,500 | $0.00 | $0.00 | filing |
| 2026-02-13 | Bhalla Narinder Pal· Chief Medical Officer | Award | 49,500 | $0.00 | $0.00 | filing |
| 2026-02-04 | Townsend Richard Nolan· Chief Executive Officer | Award | 161,665 | $0.00 | $0.00 | filing |
| 2026-02-04 | Otero Jose Manuel· Chief Operating Officer | Award | 65,000 | $0.00 | $0.00 | filing |
| 2026-02-04 | Tamayo Louis Edward· Chief Financial Officer | Award | 44,665 | $0.00 | $0.00 | filing |
| 2025-11-18 | Townsend Richard Nolan· Chief Executive Officer | Sale | 1,127 | $9.27 | $10,447.29 | filing |
| 2025-11-18 | Otero Jose Manuel· Chief Operating Officer | Sale | 721 | $9.27 | $6,683.67 | filing |
| 2025-11-18 | Adler Eric· Chief Medical Officer | Sale | 615 | $9.27 | $5,701.05 | filing |
| 2025-11-18 | Robertson Jenny· Chief Legal Officer | Sale | 549 | $9.27 | $5,089.23 | filing |
| 2025-11-18 | See Tai Sandi· Chief Development Officer | Sale | 386 | $9.27 | $3,578.22 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.